Provided by Tiger Trade Technology Pte. Ltd.

Eton Pharmaceuticals, Inc.

57.08
-0.8000-1.38%
Post-market: 57.080.00000.00%16:15 EDT
Volume:323.29K
Turnover:18.51M
Market Cap:1.63B
PE:146.36
High:59.98
Open:58.99
Low:56.45
Close:57.88
52wk High:66.37
52wk Low:14.27
Shares:28.58M
Float Shares:22.30M
Volume Ratio:0.78
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3900
EPS(LYR):-0.1710
ROE:35.97%
ROA:11.86%
PB:35.02
PE(LYR):-333.82

Loading ...

GUIDANCE: (ETON) Eton Pharmaceuticals Expects Full Year 2026 Revenue Over $145M, vs. FactSet Est of $121.3M

MT Newswires Live
·
Aug 14

Eton Pharmaceuticals Q2 Net Income USD 11.578 Million

Reuters
·
Aug 14

Eton Pharmaceuticals Inc: ‍Company NOW Expects 2026 Revenues to Exceed $145 Mln​

THOMSON REUTERS
·
Aug 14

Eton Pharmaceuticals Inc: ‍ Company NOW Expects to Report at Least a 35% Adjusted Ebitda Margin in 2026​

THOMSON REUTERS
·
Aug 14

Eton Pharmaceuticals Q2 EPS USD 0.35

THOMSON REUTERS
·
Aug 14

U.S. Earnings Preview: After Market Close Aug. 13

Dow Jones
·
Aug 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), Eton Pharmaceuticals (ETON) and Dyadic International (DYAI)

TIPRANKS
·
Aug 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13

What Could Eton Pharmaceuticals (ETON) Gain From The ASN 001 Licensing Deal?

Simply Wall St.
·
Aug 13

Eton Pharma COO Danka Radosavljevic Files Initial Beneficial Ownership Statement

Reuters
·
Aug 13

Eton Pharmaceuticals Inc Expected to Post Earnings of 11 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Eton Pharmaceuticals Inc : H.c. Wainwright Raises Target Price to $65 from $57

THOMSON REUTERS
·
Aug 11

Earning Preview: Eton Pharmaceuticals, Inc. Q2 revenue is expected to increase by 62.24%, and institutional views are bullish

Earnings Agent
·
Aug 06

Eton Pharmaceuticals Plans ASN-001 NDA Submission in 2H 2027 After Infantile Hemangioma Phase Ii/iii Data

Reuters
·
Aug 05

Eton Pharmaceuticals Licenses US Rights to Auson’s ASN-001 for Infantile Hemangiomas

Reuters
·
Aug 05

Eton Pharmaceuticals - Anticipates Nda Submission for Asn-001 in 2H 2027, Potential Launch in 2028

THOMSON REUTERS
·
Aug 05

Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate Asn-001

THOMSON REUTERS
·
Aug 05

Eton Pharmaceuticals Names Danka Radosavljevic Chief Operating Officer

Reuters
·
Aug 04

Eton Pharma to Report Q2 2026 Results, Host Conference Call and Webcast

Reuters
·
Aug 03

Is Eton Pharmaceuticals (ETON) Quietly Reframing Its Orphan-Drug Strategy With KHINDIVI’s Label Expansion Bid?

Simply Wall St.
·
Jul 30